{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicowbjmluxe4h64zmobuiiigz7awtsyo7jdnz6gmcs2g2nxwdhlny",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mg3e3opqu7r2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie6ermzepyjvde55cu53q7bta4jxhb3ggh23dmlvp4sptwwgykldm"
    },
    "mimeType": "image/jpeg",
    "size": 372155
  },
  "path": "/news/2026-03-belzutifanpembrolizumab-surgery-kidney-cancer-patients.html",
  "publishedAt": "2026-03-02T07:10:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.",
  "title": "Belzutifan+pembrolizumab post-surgery helps kidney cancer patients at high risk for relapse stay cancer-free longer"
}